BCR and acute myeloid leukemia: RUNX1 mutations were previously reported to have significant association with minimally differentiated AML (M0 by the French-American-British [FAB] classification), and analysis of gene expression profiles showed that RUNX1-mutated AML had significant upregulation of the BCR pathway25–27.